John de Kruif
Chief Tech/Sci/R&D Officer bij MERUS N.V.
Profiel
Currently, John de Kruif occupies the position of Chief Technology Officer & Senior Vice President of Merus NV.
He previously held the position of Director-Antibody Discovery at Crucell NV.
He received a doctorate from the University of Utrecht.
Actieve functies van John de Kruif
Bedrijven | Functie | Begin |
---|---|---|
MERUS N.V. | Chief Tech/Sci/R&D Officer | 01-04-2007 |
Eerdere bekende functies van John de Kruif
Bedrijven | Functie | Einde |
---|---|---|
Crucell NV
Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | Corporate Officer/Principal | 01-10-2006 |
Opleiding van John de Kruif
University of Utrecht | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
MERUS N.V. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Crucell NV
Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | Health Technology |